Udvalget konkluderede, at Gliolan gør det lettere at skelne svulsten fra det sunde væv under operationen, og at det øger den andel af patienterne, hvis svulst bliver fuldstændig fjernet, og forlænger det tidsrum, hvori patienterne overlever uden fremadskriden af sygdommen.
It concluded that Gliolan increases the ability of the tumour to be distinguished from healthy brain tissue during surgery, and that it increases the proportion of patients whose tumours are completely removed and extends the time that patients survive without progression.